Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

On May 15, 2025 , the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market.

Scientists are aiming to determine the composition and topology of physiological Ashwell-Morell receptor ligands. Their findings will help uncover the receptor's still-hidden secrets.

City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

Cash and cash equivalents as of March 31, 2025 were $102.3 million. Due in part to the strategic restructuring and ...

Petosemtamab employs three distinct mechanisms of action: EGFR ligand blocking, EGFR receptor internalization and degradation in LGR5+ cells, and Fc-mediated activation of the innate immune system by ...